Characteristic All (N=2494) Women (N=1592) Men (N=902)
Age [mean (SD)] 58.7 (15.7) 60.6 (15.5) 55.5 (15.6)
Primary inflammatory disease diagnosis
Spondylarthritis
812 (32.6%)
359 (22.6%)
453 (50.2%)
Rheumatoid Arthritis
538 (21.6%)
424 (26.6%)
114 (12.6%)
Osteoarthritis
627 (25.1%)
480 (30.2%)
147 (16.3%)
Systemic autoimmune rheumatic diseases
165 (6.62%)
149 (9.36%)
16 (1.77%)
Vasculitis
59 (2.37%)
37 (2.32%)
22 (2.44%)
Other rheumatic diseases
38 (1.52%)
26 (1.63%)
12 (1.33%)
Juvenile Arthritis
7 (0.28%)
4 (0.25%)
3 (0.33%)
Dermatological diseases
208 (8.34%)
82 (5.15%)
126 (14.0%)
Other
40 (1.60%)
31 (1.95%)
9 (1.00%)
Coexisting conditions
Hypertension
858 (34.4%)
553 (34.7%)
305 (33.8%)
Diabetes
302 (12.1%)
174 (10.9%)
128 (14.2%)
Pulmonary disease
364 (14.6%)
241 (15.1%)
123 (13.6%)
CV disease
290 (11.6%)
179 (11.2%)
111 (12.3%)
Chronic kidney disease
129 (5.17%)
76 (4.77%)
53 (5.88%)
Cancer or active treatment
70 (2.81%)
47 (2.95%)
23 (2.55%)
History of organ transplantation
8 (0.32%)
7 (0.44%)
1 (0.11%)
Any of these conditions
1223 (49.0%)
797 (50.1%)
426 (47.2%)
Treatments followed
Biologic DMARDs1 1112 (44.6%) 579 (36.4%) 533 (59.1%)
Any TNFα antagonist 768 (30.8%) 388 (24.4%) 380 (42.1%)
Adalimumab
367 (14.7%)
163 (10.2%)
204 (22.6%)
Etanercept
183 (7.34%)
105 (6.60%)
78 (8.65%)
Infliximab
120 (4.81%)
60 (3.77%)
60 (6.65%)
Golimumab
65 (2.61%)
35 (2.20%)
30 (3.33%)
Certolizumab
33 (1.32%)
25 (1.57%)
8 (0.89%)
Any pro-inflammatory ILs antagonists 279 (11.2%) 136 (8.54%) 143 (15.9%)
IL-6 antagonists 52 (2.09%) 42 (2.64%) 10 (1.11%)
Tocilizumab
46 (1.84%)
37 (2.32%)
9 (1.00%)
Sarilumab
6 (0.24%)
5 (0.31%)
1 (0.11%)
IL-17 antagonists 69 (24.7%) 26 (19.1%) 43 (30.1%)
Brodalumab
2 (0.72%)
1 (0.74%)
1 (0.70%)
Secukinumab
51 (2.04%)
22 (1.38%)
29 (3.22%)
Ixekizumab
16 (5.73%)
3 (2.21%)
13 (9.09%)
IL-23(12) antagonists
158 (56.6%)
68 (50.0%)
90 (62.9%)
Ustekinumab
155 (6.21%)
67 (4.21%)
88 (9.76%)
Guselkumab
3 (1.08%)
1 (0.74%)
2 (1.40%)
Any T lymphocyte antagonist 29 (1.16%) 22 (1.38%) 7 (0.78%)
Any B lymphocyte antagonist 42 (1.68%) 36 (2.26%) 6 (0.67%)
Vedolizumab 3 (0.12%) 2 (0.13%) 1 (0.11%)
Synthetic DMARDs2 850 (34.1%) 583 (36.6%) 267 (29.6%)
Methotrexate 538 (21.6%) 366 (23.0%) 172 (19.1%)
Leflunomide 116 (4.65%) 86 (5.40%) 30 (3.33%)
Chloroquine or Hydroxychloroquine 115 (4.61%) 105 (6.60%) 10 (1.11%)
Azathioprine 80 (3.21%) 52 (3.27%) 28 (3.10%)
JAK inhibitors 41 (1.64%) 32 (2.01%) 9 (1.00%)
Apremilast 52 (2.09%) 20 (1.26%) 32 (3.55%)
Sulfasalazine 10 (0.40%) 7 (0.44%) 3 (0.33%)
Mycophenolate 19 (0.76%) 17 (1.07%) 2 (0.22%)
Tacrolimus 24 (0.96%) 17 (1.07%) 7 (0.78%)
Cyclosporine 3 (0.12%) 2 (0.13%) 1 (0.11%)
Dose of Glucocorticoids:
≤10 mg/d 441 (17.7%) 347 (21.8%) 94 (10.4%)
>10 mg/d 86 (3.45%) 62 (3.89%) 24 (2.66%)
Anti-hypertensive drugs3 684 (27.4%) 428 (26.9%) 256 (28.4%)
ACE inhibitors 397 (15.9%) 237 (14.9%) 160 (17.7%)
ARBs 293 (11.7%) 194 (12.2%) 99 (11.0%)
Chronic NSAIDs 498 (20.0%) 345 (21.7%) 153 (17.0%)
COVID-19 status
Confirmed or high suspected COVID-19 symptoms 156 (6.26%) 108 (6.78%) 48 (5.32%)
SARS-CoV-2 test:
Not tested with hsCOVID-19 symptoms 122 (4.89%) 87 (5.46%) 35 (3.88%)
Positive
34 (1.36%)
21 (1.32%)
13 (1.44%)
Hospitalization due to COVID-19 26 (1.04%) 18 (1.13%) 8 (0.89%)
Deaths due to COVID-19 4 (0.16%) 2 (0.13%) 2 (0.22%)
CV= cardiovascular. DMARDs= disease modifying antirheumatic drugs. JAK=Janus kinase. IL=interleukin. TNF=tumor necrosis factor. NSAIDs= non-steroid anti-inflammatory drugs. ACE= angiotensin-converting enzyme. ARBs= angiotensin II receptor blockers. 1Biologic DMARDs include TNF antagonists, pro-inflammatory ILs antagonists, vedolilzumab and T and B lymphocyte antagonists. 2Synthetic DMARDs include methotrexate, JAK inhibitors, sulfasalazine, mycophenolate, tacrolimus, azathioprine, cyclosporine, chloroquine or hydroxychloroquine and leflunomide and apremilast. 3Anti-hypertensive drugs include ACE inhibitors and ARBs. CV= cardiovascular. DMARDs= disease modifying antirheumatic drugs. JAK=Janus kinase. IL=interleukin. TNF=tumor necrosis factor. NSAIDs= non-steroid anti-inflammatory drugs. ACE= angiotensin-converting enzyme. ARBs= angiotensin II receptor blockers. 1Biologic DMARDs include TNF antagonists, pro-inflammatory ILs antagonists, vedolilzumab and T and B lymphocyte antagonists. 2Synthetic DMARDs include methotrexate, JAK inhibitors, sulfasalazine, mycophenolate, tacrolimus, azathioprine, cyclosporine, chloroquine or hydroxychloroquine and leflunomide and apremilast. 3Anti-hypertensive drugs include ACE inhibitors and ARBs. CV= cardiovascular. DMARDs= disease modifying antirheumatic drugs. JAK=Janus kinase. IL=interleukin. TNF=tumor necrosis factor. NSAIDs= non-steroid anti-inflammatory drugs. ACE= angiotensin-converting enzyme. ARBs= angiotensin II receptor blockers. 1Biologic DMARDs include TNF antagonists, pro-inflammatory ILs antagonists, vedolilzumab and T and B lymphocyte antagonists. 2Synthetic DMARDs include methotrexate, JAK inhibitors, sulfasalazine, mycophenolate, tacrolimus, azathioprine, cyclosporine, chloroquine or hydroxychloroquine and leflunomide and apremilast. 3Anti-hypertensive drugs include ACE inhibitors and ARBs. CV= cardiovascular. DMARDs= disease modifying antirheumatic drugs. JAK=Janus kinase. IL=interleukin. TNF=tumor necrosis factor. NSAIDs= non-steroid anti-inflammatory drugs. ACE= angiotensin-converting enzyme. ARBs= angiotensin II receptor blockers. 1Biologic DMARDs include TNF antagonists, pro-inflammatory ILs antagonists, vedolilzumab and T and B lymphocyte antagonists. 2Synthetic DMARDs include methotrexate, JAK inhibitors, sulfasalazine, mycophenolate, tacrolimus, azathioprine, cyclosporine, chloroquine or hydroxychloroquine and leflunomide and apremilast. 3Anti-hypertensive drugs include ACE inhibitors and ARBs.